A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL

Toby Eyre; Catherine Hildyard; Angela Hamblin; Ayesha S. Ali; Aimee Houlton; Louise Hopkins; Daniel Royston; Kim M. Linton; Andrew Pettitt; Simon Rule; Kate Cwynarski; Sally F. Barrington; Victoria Warbey; David Wrench; Sharon Barrans; Caroline S. Hirst; Anesh Panchal; Martine P. Roudier; Elizabeth A. Harrington; Andrew Davies; Graham P. Collins

doi:10.1002/hon.2662

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL

Toby Eyre, Catherine Hildyard, Angela Hamblin, Ayesha S. Ali, Aimee Houlton, Louise Hopkins, Daniel Royston, Kim M. Linton, Andrew Pettitt, Simon Rule, Kate Cwynarski, Sally F. Barrington, Victoria Warbey, David Wrench, Sharon Barrans, Caroline S. Hirst, Anesh Panchal, Martine P. Roudier, Elizabeth A. Harrington, Andrew DaviesGraham P. Collins

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Hematological Oncology
DOIs	https://doi.org/10.1002/hon.2662
Publication status	Published - Oct 2019

Access to Document

10.1002/hon.2662

Cite this

Eyre, T., Hildyard, C., Hamblin, A., Ali, A. S., Houlton, A., Hopkins, L., Royston, D., Linton, K. M., Pettitt, A., Rule, S., Cwynarski, K., Barrington, S. F., Warbey, V., Wrench, D., Barrans, S., Hirst, C. S., Panchal, A., Roudier, M. P., Harrington, E. A., ... Collins, G. P. (2019). A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. Hematological Oncology. https://doi.org/10.1002/hon.2662

@article{fdae85cd39b94d789b9d19f0b00e746e,

title = "A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL",

author = "Toby Eyre and Catherine Hildyard and Angela Hamblin and Ali, {Ayesha S.} and Aimee Houlton and Louise Hopkins and Daniel Royston and Linton, {Kim M.} and Andrew Pettitt and Simon Rule and Kate Cwynarski and Barrington, {Sally F.} and Victoria Warbey and David Wrench and Sharon Barrans and Hirst, {Caroline S.} and Anesh Panchal and Roudier, {Martine P.} and Harrington, {Elizabeth A.} and Andrew Davies and Collins, {Graham P.}",

year = "2019",

month = oct,

doi = "10.1002/hon.2662",

language = "English",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "Wiley",

}

Eyre, T, Hildyard, C, Hamblin, A, Ali, AS, Houlton, A, Hopkins, L, Royston, D, Linton, KM, Pettitt, A, Rule, S, Cwynarski, K, Barrington, SF, Warbey, V, Wrench, D, Barrans, S, Hirst, CS, Panchal, A, Roudier, MP, Harrington, EA, Davies, A & Collins, GP 2019, 'A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL', Hematological Oncology. https://doi.org/10.1002/hon.2662

TY - JOUR

T1 - A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL

AU - Eyre, Toby

AU - Hildyard, Catherine

AU - Hamblin, Angela

AU - Ali, Ayesha S.

AU - Houlton, Aimee

AU - Hopkins, Louise

AU - Royston, Daniel

AU - Linton, Kim M.

AU - Pettitt, Andrew

AU - Rule, Simon

AU - Cwynarski, Kate

AU - Barrington, Sally F.

AU - Warbey, Victoria

AU - Wrench, David

AU - Barrans, Sharon

AU - Hirst, Caroline S.

AU - Panchal, Anesh

AU - Roudier, Martine P.

AU - Harrington, Elizabeth A.

AU - Davies, Andrew

AU - Collins, Graham P.

PY - 2019/10

Y1 - 2019/10

UR - http://dx.doi.org/10.1002/hon.2662

U2 - 10.1002/hon.2662

DO - 10.1002/hon.2662

M3 - Article

SN - 0278-0232

JO - Hematological Oncology

JF - Hematological Oncology

ER -